Who is sponsoring NCT02545842?

NCT02545842 is sponsored by Sanofi.

What condition does NCT02545842 study?

NCT02545842 studies Type 2 Diabetes Mellitus.

What drugs are being tested in NCT02545842?

Interventions: INSULIN GLARGINE.

What is the status of NCT02545842?

NCT02545842 is currently COMPLETED.

Last reviewed 2022-04-25 · How we verify

Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

NCT02545842 PHASE4 COMPLETED

Primary Objective: To identify a best fasting plasma glucose (FPG) target for Chinese type 2 diabetes patients using insulin glargine which can provide the highest control rate of glycated hemoglobin (HbA1c) \< 7%. Secondary Objectives: The control rate of HbA1c ≤6.5% achievement. The control rate of HbA1c \<7.0% in patients achieving their FPG target. The percentage of HbA1c \<7% without hypoglycemia. The percentage of patients achieving the FPG target without hypoglycemia. The percentage of patients achieving the FPG target and post prandial glucose (PPG) target (2-hour post breakfast \<10 mmol/L).

Details

Lead sponsor	Sanofi
Phase	PHASE4
Status	COMPLETED
Enrolment	947
Start date	Mon Sep 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Apr 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Type 2 Diabetes Mellitus

Interventions

INSULIN GLARGINE

Countries

China